PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

Completed

Conditions: Melanoma

Interventions: Drug: Encorafenib
Drug: Dabrafenib
Drug: Vemurafenib
Drug: Binimetinib
Drug: Cobimetinib
Drug: Trametinib

First Posted Date: 2022-03-02

Last Posted Date: 2025-03-06

Lead Sponsor: Pfizer

Target Recruit Count: 716

Registration Number: NCT05260684

Locations: 🇺🇸
Pfizer Investigational Site, New York, New York, United States

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders

Phase 3

Terminated

Conditions: Temporomandibular Disorders (TMD)

Interventions: Drug: Placebo
Drug: Rimegepant

First Posted Date: 2022-03-02

Last Posted Date: 2024-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 126

Registration Number: NCT05262517

Locations: 🇺🇸
The Medici Medical Research, LLC, Hollywood, Florida, United States
🇺🇸
The Medici Medical Research, Hollywood, Florida, United States
🇺🇸
Clinvest Research, LLC, Springfield, Missouri, United States

and more 29 locations

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1

Withdrawn

Conditions: Bladder Cancer

Interventions: Drug: PF-07225570
Drug: sasanlimab

First Posted Date: 2022-02-28

Last Posted Date: 2023-03-08

Lead Sponsor: Pfizer

Registration Number: NCT05259397

Locations: 🇵🇱
Szpital Specjalistyczny im. Sw. Rodziny SPZOZ, Warszawa, Poland
🇵🇱
Medical Concierge Centrum Medyczne, Warszawa, Poland
🇺🇸
Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States

and more 1 locations

A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Other: Placebo
Drug: IFN-β inhibitor treatment

First Posted Date: 2022-02-25

Last Posted Date: 2024-08-14

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT05257798

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China

A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

Terminated

Conditions: Dermatitis, Atopic

First Posted Date: 2022-02-22

Last Posted Date: 2024-11-01

Lead Sponsor: Pfizer

Target Recruit Count: 112

Registration Number: NCT05250115

Locations: 🇩🇪
Elbe Kliniken Stade - Buxtehude GmbH, Buxtehude, Niedersachsen, Germany
🇩🇪
ÜUeberoertliche Gemeinschaftspraxis Jost Kai Rietkoetter Robert Jablonka, Gelsenkirchen, Nordrhein-westfalen, Germany
🇩🇪
Dermatologische Gemeinschaftspraxis Dres. Quist PartG, Mainz, Rheinland-pfalz, Germany

and more 35 locations

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

Phase 3

Completed

Conditions: Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

Interventions: Drug: rimegepant 75 mg ODT
Drug: Matching placebo

First Posted Date: 2022-02-21

Last Posted Date: 2025-03-26

Lead Sponsor: Pfizer

Target Recruit Count: 261

Registration Number: NCT05248997

Locations: 🇺🇸
San Diego Clinical Research Center, La Mesa, California, United States
🇺🇸
Velocity Clinical San Diego, La Mesa, California, United States
🇺🇸
National Research Institute, Panorama City, California, United States

and more 30 locations

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Conditions: Multiple Myeloma

First Posted Date: 2022-02-14

Last Posted Date: 2025-02-04

Lead Sponsor: Pfizer

Registration Number: NCT05238311

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Urothelial Cancer
Advanced Solid Tumors
Gastroesophageal Junction Cancer
Gastric Cancer
Non Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinomas

Interventions: Drug: PF-07265028
Biological: Sasanlimab

First Posted Date: 2022-02-10

Last Posted Date: 2024-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 21

Registration Number: NCT05233436

Locations: 🇺🇸
Napa Research, Margate, Florida, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States

and more 9 locations

Voxelotor Brain Oxygenation and Neurocognitive Study

Phase 4

Withdrawn

Conditions: Sickle Cell Disease

Interventions: Drug: Voxelotor Oral Tablet

First Posted Date: 2022-02-08

Last Posted Date: 2024-08-09

Lead Sponsor: Pfizer

Registration Number: NCT05228821

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
The Children's Hospital at Montefiore, Bronx, New York, United States

Voxelotor Neurocognitive Function Study

Phase 3

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Placebo
Drug: Voxelotor Only Product in Oral Dose Form

First Posted Date: 2022-02-08

Last Posted Date: 2024-05-02

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05228834

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy